Published in Nat Immunol on August 28, 2011
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity (2014) 1.82
The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol (2011) 1.76
Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med (2013) 1.08
USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol (2014) 1.06
Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells. Nat Immunol (2012) 1.05
Regulation of nuclear factor-κB in autoimmunity. Trends Immunol (2013) 1.05
Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance. Cell Mol Immunol (2012) 1.04
Pellino3 targets the IRF7 pathway and facilitates autoregulation of TLR3- and viral-induced expression of type I interferons. Nat Immunol (2012) 0.96
TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J Exp Med (2013) 0.93
Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity. Immunity (2014) 0.92
Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nat Immunol (2013) 0.92
Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation. Mol Syst Biol (2015) 0.92
K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8(+) T cell activation. Nat Immunol (2015) 0.88
E3 ubiquitin ligases Pellinos as regulators of pattern recognition receptor signaling and immune responses. Immunol Rev (2015) 0.87
A key role for NF-κB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin Dev Immunol (2012) 0.85
Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. J Clin Invest (2014) 0.83
Ubiquitin signaling in immune responses. Cell Res (2016) 0.80
Peli1 (rel)ieves autoimmunity. Nat Immunol (2011) 0.80
NF-κB and Rheumatoid Arthritis: Will Understanding Genetic Risk Lead to a Therapeutic Reward? For Immunopathol Dis Therap (2013) 0.79
Peli1 sets the CNS on fire. Nat Med (2013) 0.79
CD8+ Treg cells suppress CD8+ T cell-responses by IL-10-dependent mechanism during H5N1 influenza virus infection. Eur J Immunol (2013) 0.79
Tripartite motif-containing protein 30 modulates TCR-activated proliferation and effector functions in CD4+ T cells. PLoS One (2014) 0.78
Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation. Cell Death Differ (2014) 0.78
TRAF3, ubiquitination, and B-lymphocyte regulation. Immunol Rev (2015) 0.78
Pellino-3 promotes endotoxin tolerance and acts as a negative regulator of TLR2 and TLR4 signaling. J Leukoc Biol (2015) 0.78
The pellino e3 ubiquitin ligases recognize specific phosphothreonine motifs and have distinct substrate specificities. Biochemistry (2014) 0.78
Toll-like receptor 2 in host defense against Mycobacterium tuberculosis: to be or not to be-that is the question. Curr Opin Immunol (2016) 0.78
Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide. EMBO Mol Med (2015) 0.77
TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex. Mol Immunol (2015) 0.77
Peli1 negatively regulates type I interferon induction and antiviral immunity in the CNS. Cell Biosci (2015) 0.77
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination. Oncotarget (2016) 0.76
PELI1 expression is correlated with MYC and BCL6 expression and associated with poor prognosis in diffuse large B-cell lymphoma. Mod Pathol (2016) 0.76
Ubiquitous points of control over regulatory T cells. J Mol Med (Berl) (2014) 0.76
A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J Exp Med (2016) 0.75
The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. J Proteomics Bioinform (2016) 0.75
Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications. Am J Clin Exp Immunol (2014) 0.75
Identification of miRNA-mRNA crosstalk in CD4(+) T cells during HIV-1 infection by integrating transcriptome analyses. J Transl Med (2017) 0.75
Advantages of Extracellular Ubiquitin in Modulation of Immune Responses. Mediators Inflamm (2016) 0.75
Ubiquitylation as a Rheostat for TCR Signaling: From Targeted Approaches Toward Global Profiling. Front Immunol (2015) 0.75
Transcriptional Profiling of Th2 Cells Identifies Pathogenic Features Associated with Asthma. J Immunol (2016) 0.75
Does antigen masking by ubiquitin chains protect from the development of autoimmune diseases? Front Immunol (2014) 0.75
The Ubiquitination of NF-κB Subunits in the Control of Transcription. Cells (2016) 0.75
Ubiquitin enzymes in the regulation of immune responses. Crit Rev Biochem Mol Biol (2017) 0.75
Shared principles in NF-kappaB signaling. Cell (2008) 20.96
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
T cell activation. Annu Rev Immunol (2009) 7.40
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell (2008) 5.89
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell (2001) 5.88
Mechanisms of suppression by suppressor T cells. Nat Immunol (2005) 5.52
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev (1995) 5.51
Ubiquitylation in innate and adaptive immunity. Nature (2009) 4.60
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol (2007) 3.02
Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 2.89
Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol (2006) 2.73
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
Ubiquitin ligases and the immune response. Annu Rev Immunol (2004) 2.14
Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med (2007) 2.14
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest (2002) 1.96
Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol (2009) 1.86
CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol (1997) 1.83
The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem J (2008) 1.68
NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. J Biol Chem (1998) 1.60
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology (2008) 1.59
T cell anergy and costimulation. Immunol Rev (2003) 1.52
Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol (2004) 1.50
c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol (1999) 1.48
The Pellino family: IRAK E3 ligases with emerging roles in innate immune signalling. Trends Immunol (2008) 1.43
Pellino proteins are more than scaffold proteins in TLR/IL-1R signalling: a role as novel RING E3-ubiquitin-ligases. FEBS Lett (2006) 1.42
Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev (2009) 1.38
Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood (2009) 1.29
New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J Immunol (2009) 1.26
Kinase-active interleukin-1 receptor-associated kinases promote polyubiquitination and degradation of the Pellino family: direct evidence for PELLINO proteins being ubiquitin-protein isopeptide ligases. J Biol Chem (2007) 1.23
T cell-intrinsic expression of c-Rel regulates Th1 cell responses essential for resistance to Toxoplasma gondii. J Immunol (2004) 1.23
Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol (2009) 1.20
Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b. Semin Immunol (2007) 1.17
Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma (2004) 1.16
Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells. Mol Cell Biol (1994) 1.13
Regulation of the IL-21 gene by the NF-κB transcription factor c-Rel. J Immunol (2010) 1.10
Regulatory T cells: immune suppression and beyond. Cell Mol Immunol (2010) 1.09
Pellino proteins: novel players in TLR and IL-1R signalling. J Cell Mol Med (2007) 1.08
c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity (2005) 1.07
Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol Rev (2008) 1.05
NF-kappa B1 p105 regulates T cell homeostasis and prevents chronic inflammation. J Immunol (2009) 1.00
Regulation of the interleukin-2 CD28-responsive element by NF-ATp and various NF-kappaB/Rel transcription factors. Mol Cell Biol (1997) 1.00
Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol (2002) 0.99
Smad7 and Smad6 bind to discrete regions of Pellino-1 via their MH2 domains to mediate TGF-beta1-induced negative regulation of IL-1R/TLR signaling. Biochem Biophys Res Commun (2010) 0.94
The roles of c-rel and interleukin-2 in tolerance: a molecular explanation of self-nonself discrimination. Immunol Cell Biol (2010) 0.90
Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway. J Biol Chem (1998) 0.83
c-Rel phenocopies PKCtheta but not Bcl-10 in regulating CD8+ T-cell activation versus tolerance. Eur J Immunol (2010) 0.81
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Bcl6 mediates the development of T follicular helper cells. Science (2009) 8.50
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature (2005) 4.60
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med (2011) 4.50
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell (2002) 4.33
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A (2009) 4.10
Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell (2003) 4.07
Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med (2007) 3.91
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 3.42
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem (2004) 3.35
A gene in the multidrug and toxic compound extrusion (MATE) family confers aluminum tolerance in sorghum. Nat Genet (2007) 3.19
Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J (2005) 2.99
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity (2008) 2.78
Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol (2006) 2.73
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med (2009) 2.63
Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol (2002) 2.60
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol (2013) 2.46
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem (2004) 2.30
The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure (2010) 2.29
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol (2012) 2.18
Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med (2007) 2.14
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 2.10
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell (2007) 2.05
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol (2002) 1.92
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J Biol Chem (2002) 1.90
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol (2009) 1.86
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res (2003) 1.81
Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem (2004) 1.79
The RIG-I-like receptor LGP2 recognizes the termini of double-stranded RNA. J Biol Chem (2009) 1.78
Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem (2008) 1.78
IkappaB kinase is an essential component of the Tpl2 signaling pathway. Mol Cell Biol (2004) 1.76
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-κB signaling. Nat Immunol (2012) 1.68
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine (2009) 1.68
Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol (2005) 1.61
Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol (2012) 1.57
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Deletion of G protein-coupled receptor 48 leads to ocular anterior segment dysgenesis (ASD) through down-regulation of Pitx2. Proc Natl Acad Sci U S A (2008) 1.53
Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest (2008) 1.53
Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest (2006) 1.53
Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol (2006) 1.49
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res (2003) 1.46
Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. J Biol Chem (2008) 1.46
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother (2011) 1.46
ERβ and PEA3 co-activate IL-8 expression and promote the invasion of breast cancer cells. Cancer Biol Ther (2011) 1.45
MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol (2009) 1.44
Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res (2007) 1.44
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine (2011) 1.43
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol (2009) 1.43